Skip to main content
보도자료 배포 뉴스와이어
검색폼
검색
로그인
회원가입
보도자료
서비스
교육
블로그
보도자료 배포
보도자료 구독
고객센터
보도자료 배포 서비스
보도자료 배포 뉴스와이어
보도자료 배포
보도자료 구독
고객센터
로그인
회원가입
보도자료
서비스
교육
블로그
통합검색
보도자료
사진
동영상
기업
박람회
FAQ
취소
기업 검색
보도자료 등록
최신
IT
건강
경제
교육
금융
농수산
라이프
레저
문화
미디어
부동산
사회
산업
스포츠
에너지
운송
유통
자동차
정책
신상품
상장기업
주요
최신 보도자료
MY뉴스
상장기업
사진
동영상
기업뉴스룸
박람회
인기 토픽
보도자료 분야와 RSS
English News
산업별
IT
건강
경제
교육
금융
농수산
라이프 스타일
레저
문화/연예
미디어
산업별
부동산
사회
산업
스포츠
에너지/환경
운송
유통
자동차
정책/정부
주제별
개발
공모/모집
기업문화
부고
분양
사업계획
사회공헌
선언/의견
설립/오픈
소송
수상/선정
수주
주제별
신상품
실적
인물동정
인사
인수/합병
전시/출품
정책
제휴
조사연구
채용
투자
판촉활동
지역별
서울
인천/경기
대전/충남
광주/전남
부산/울산/경남
대구/경북
강원
충북
전북
제주
해외
기업 뉴스룸
Boehringer Ingelheim International GmbH
이 회사 보도자료 구독
제약
INGELHEIM, Germany
http://www.boehringer-ingelheim.com
Boehringer Ingelheim International GmbH 보도자료
337개
RSS
이메일
2019년 8월 30일
17:20
Anniversary of the pivotal RE-LY® trial marks a decade of innovation for stroke prevention in AF patients
Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication[1-3] recognising the contribution made in the decade since by patients, healthcare professionals (HCPs) and researchers. In the fifty years prior, warfar
건강
제약
개발
2019년 8월 13일
09:48
Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer therapies
Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung c
건강
제약
제휴
2019년 7월 16일
13:03
Boehringer Ingelheim Acquires AMAL Therapeutics, Significantly Enriching Its Cancer Immunology Portfolio with Novel Cancer Vaccines Platform
Boehringer Ingelheim today announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology pla
건강
제약
인수/합병
2019년 7월 9일
17:29
Dabigatran’s safety and efficacy established for management of VTE in children
Boehringer Ingelheim today announced results from two paediatric studies of dabigatran etexilate, which were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia.[1,2] The data showed da
건강
제약
개발
2019년 7월 2일
09:22
Boehringer Ingelheim Expands Nonalcoholic Steatohepatitis (NASH) R&D Pipeline With New First-in-Class Compound from Yuhan Corporation
Boehringer Ingelheim and Yuhan Corporation today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of NASH and related liver diseases that combines GLP-1 and FGF21 activity in one m
건강
제약
제휴
2019년 6월 18일
10:16
Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors
Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal
건강
제약
개발
2019년 6월 12일
10:19
Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance
Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins. This brings together the expertise of Professo
건강
제약
제휴
2019년 6월 11일
14:59
Full data from CAROLINA® outcome trial support long-term cardiovascular safety profile of Trajenta®
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced full data from the CAROLINA® trial demonstrating that Trajenta® (linagliptin) did not increase cardiovascular risk compared to glimepiride in adults with type 2 diabetes and cardiov
건강
제약
개발
2019년 6월 11일
10:18
New post-hoc analysis shows consistent cardiorenal risk reductions of empagliflozin in a sub-group of adults with type 2 diabetes and chronic kidney disease without overt proteinuria
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a new post-hoc analysis of data from the EMPA-REG OUTCOME® trial. These results indicated that the effect of empagliflozin on reducing cardiovascular and renal risk
건강
제약
개발
2019년 5월 29일
18:19
Boehringer Ingelheim and Gubra announce new collaboration to develop anti-obesity peptide poly-agonists
Boehringer Ingelheim and Gubra announce a second collaboration and license agreement for the development of novel poly-agonist peptides to treat obesity. It will bring together Gubra’s established expertise in the design, synthesis, pharmaceutical ch
건강
제약
제휴
2019년 5월 24일
09:30
Network of 1,500 Stroke-Ready Clinics across Europe
The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved. The Angels Initia
건강
제약
사업계획
2019년 5월 22일
09:43
Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis associated ILD[1]
Boehringer Ingelheim today announced that the SENSCIS® trial met its primary endpoint: reduction in the annual rate of decline in forced vital capacity (FVCa) in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD). Results
건강
제약
개발
2019년 5월 16일
19:49
Trial results of Pradaxa® vs ASA in ESUS published in NEJM
Boehringer Ingelheim today announced full results from the RE-SPECT ESUS® trial, a Phase III randomised, double-blind study investigating the efficacy and safety of Pradaxa® (dabigatran etexilate) versus acetylsalicylic acid (ASA) in preventing recur
건강
제약
개발
2019년 4월 17일
18:00
Financial year 2018: Boehringer Ingelheim grows and invests
The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2
건강
제약
실적
2019년 4월 9일
17:25
Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine
Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’. Equine lameness is truly common and impacts horse performance as well as e
건강
제약
신상품
2019년 4월 1일
11:40
Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics
Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD’s innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics
건강
제약
인수/합병
2019년 3월 28일
18:00
Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19 and AMCP 2019
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empagliflozin is associated with a 22 percent relative
건강
제약
개발
2019년 3월 19일
11:05
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA. Nintedanib as an anti-fibrotic medicine is already approved in more than 70
건강
제약
개발
2019년 2월 27일
11:05
Boehringer Ingelheim and GNA Biosolutions partner on emergency veterinary diagnostics development
Boehringer Ingelheim and GNA Biosolutions announce that they have entered into a research collaboration focused on the development of a rapid African swine fever (ASF) diagnostic test. The test would be used in combination with GNA's portable molecul
건강
제약
제휴
2019년 2월 27일
11:05
베링거 인겔하임과 GNA바이오솔루션즈, 긴급 동물 진단법 개발 위해 협업
베링거 인겔하임(Boehringer Ingelheim)과 GNA바이오솔루션즈(GNA Biosolutions, 이하 ‘GNA’)가 아프리카 돼지열병(African swine fever, ASF)의 신속한 진단 검사법을 개발하기 위한 연구 협업 계약을 체결했다고 발표했다. 이 검사법은 GNA의 휴대용 분자 진단 플랫폼과 함께 사용하는 것으로써 이처럼 치명적인 질환이 전세계에 확산되는 것을 방지하는 것을 목표로 하
건강
제약
제휴
2019년 2월 19일
16:50
Boehringer Ingelheim and Lilly’s CAROLINA® cardiovascular outcome trial for Trajenta® meets primary endpoint of non-inferiority compared to glimepiride
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority of Trajenta® (linagl
건강
제약
개발
2019년 1월 7일
10:10
Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna
Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second he
건강
제약
개발
2019년 1월 4일
18:00
Boehringer Ingelheim and Vanderbilt University Announce Partnership to Develop Novel Therapies for Psychiatric Disorders
Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) kn
건강
제약
제휴
2019년 1월 4일
10:15
Boehringer Ingelheim Initiates a Collaborative Partnership with Science 37 to Accelerate Patient Centricity in the Development of Novel Therapies
Science 37, an industry leader in virtual clinical trials, and Boehringer Ingelheim announced today a technology enterprise collaboration agreement that will support Boehringer Ingelheim in running remote clinical trials. Science 37 is licensing acce
건강
제약
제휴
2018년 12월 17일
09:25
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage I
건강
제약
개발
이전
1
2
3
4
5
다음
동영상
Final results from landmark DYNAGITO® trial published in The Lancet Respiratory Medicine
회사 보도자료 구독
뉴스와이어 회원은 이 회사 보도자료를 이메일과
MY뉴스
를 통해 무료로 구독할 수 있습니다.
회원 가입하기